Tonix Pharmaceuticals Completes Type B Pre-IND Meeting With FDA For TNX-102 SL For Treatment Of Major Depressive Disorder

Tonix anticipates filing the IND application in the fourth quarter of 2025

TNX-102 SL is a potential first-in-class treatment for targeting the disturbed sleep associated with depression

TNX-102 SL is FDA-approved for the treatment of fibromyalgia